Zen Chu
Managing Director @ Vector Ventures
Cambridge, United States
Zen Chu is a Series A investor at Vector Ventures in Cambridge focused on Health Care and Medical. Zen Chu believes that now is the best time in history for healthcare entrepreneurs and engineers to create the data, systems and products to help medicine scale and serve more patients with higher quality at lower cost. He created and teaches the MIT Healthcare Ventures graduate courses within the pioneering Health Science & Technology (HST)program, a joint initiative between MIT, Harvard Medical School and the Boston academic hospitals. As faculty director for the HackingMedicine.MIT.edu health innovation leadership initiatives, Zen mentors physician entrepreneurs, early-stage startups and health corporations adapting to global digital healthcare transformation, changing healthcare incentives, growth in emerging markets, and new disruptive technologies that re-engineer medicine.As Managing Director of Accelerated Medical Ventures, Zen specializes in building early-stage medical technology and healthcare service companies, usually serving as co-founder and first investor. AMV’s portfolio spans Boston, Silicon Valley and China, including PillPack.com, Figure1.com, 3D-Matrix Medical [JASDAQ: 7777], Curoverse Genomics, PathFinder Regenerative Medicine [OTCQB: PFND], BitGym.com, Aptible, DirectDermatology.com and a couple of companies still in stealth mode.Alongside four world-renowned MIT biomaterials professors, Zen co-founded 3D-Matrix Medical Inc., serving as the first CEO for the venture-backed MIT regenerative medicine company whose injectable gel drug delivery products are treating patients and enabling new regenerative medicine research, with a successful IPO in 2011. He has managed and led new ventures for Harvard Medical School, Harvard’s Wyss Institute for Bioengineering, NetVentures and Hewlett-Packard.Zen earned a Masters of Public & Private Management from Yale University and a BS in biomedical/electrical engineering from SMU. He's married to another entrepreneur-turned-venture investor and they are raising three aspiring makers in Brookline, MA.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Zen Chu invests in
Stages Zen Chu invests in
Countries Zen Chu invests in
Round sizes
Round size
- Seed
- $2M–$13M
- Series A
- $1.1M–$60M
Investment Focus
Industry
- Health Care 5 (71%)
- Medical 3 (43%)
- Life Science 2 (29%)
- mHealth 1 (14%)
- Delivery 1 (14%)
Stage
- Series A 4 (57%)
- Seed 3 (43%)
Country
- United States 4 (57%)
- Canada 1 (14%)
- Germany 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Molecule
|
Molecule is a software platform used to decentralise intellectual property development in the biotech industry. The company was founded in 2020 by Paul Kohlhaas and Tyler Golato and is headquartered in Schaffhausen, Switzerland. | $12.7M / Seed / Jun 13, 2022 | |
MycoMedica Life Sciences, PBC
|
Psychedelic Medicines | $60M / Series A / Jun 01, 2022 | |
Lora DiCarlo
|
Lora DiCarlo used biomimicry to translate human mouth, tongue, and finger-like haptics into microrobotic mechanisms that feel like a human partner. Osé adjusts to each woman's unique physiology for a personal fit that makes achieving the elusive blended orgasm easy. | $1.1M / Series A / Jan 03, 2022 | |
Abridge
|
Abridge provides an AI platform that transforms patient-clinician conversations into structured, billable clinical notes. This technology aims to reduce documentation burdens for clinicians and nurses. The system integrates into existing healthcare workflows and electronic health record systems. | $10M / Series A / Oct 06, 2020 | |
Filtricine
|
Filtricine, Inc. is a venture-backed, clinical stage biotech company based in Santa Clara, CA. We are developing a nutrient modulation platform which can identify metabolic vulnerabilities in cancers and exploit those vulnerabilities without the use of drugs. | $5M / Seed / Oct 29, 2018 | |
Figure 1
|
Figure 1 connects healthcare professionals around the world to view, discuss, and share medical cases. It now has a global community of millions of healthcare professionals. It was founded in 2012 and is headquartered in Toronto, Canada. | $2M / Seed / Dec 09, 2013 | |
PillPack
|
PillPack is a full-service pharmacy that sorts medication by dose and offers door-to-door delivery. They fill, sort, and deliver all medications in personalized packets based on when you need to take them. Their service helps you take the right meds at the right time, every time. | $3.5M / Series A / Jul 01, 2013 |
Co-Investors
About Vector Ventures
Vector Ventures is a early stage digital health + medical device investment fund
Vector Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Zen Chu
Managing Director
|
|||
4 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Zen Chu invest in?
Zen Chu invests primarily in Health Care, Medical and Life Science startups, most often at Series A and Seed stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Zen Chu's check size?
Zen Chu typically joins rounds of $2M–$13M at Seed and $1.1M–$60M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Zen Chu participates in.
When did Zen Chu last invest?
The most recent investment recorded for Zen Chu closed in Jun 2022. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
